# Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours

> **NCT06022692** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pengyuan Liu** · enrollment: 18 (actual)

## Conditions studied

- Gastrointestinal Tumor

## Interventions

- **DEVICE:** Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
- **DRUG:** tislelizumab (BeiGene, China) combined with PD-1 inhibitor

## Key facts

- **NCT ID:** NCT06022692
- **Lead sponsor:** Pengyuan Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2022-05-31
- **Final completion:** 2023-08-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06022692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06022692, "Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06022692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*